Non-gonococcal urethritis due to T-mycoplasma (Ureaplasma urealyticum) serotype 2 in a conjugal sexual partnership.

Ford, Denys K.; Henderson, Elizabeth

doi:10.1136/sti.52.5.341

Cited by 5 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are reports of patients with persistent or recurrent ureaplasma-positive urethritis being cured only after their sexual partner received appropriate treatment. 89 . There is conflicting evidence that partners of such men may be at increased risk of testing chlamydia-positive.…”

Section: Sexual Contacts/partnersmentioning

confidence: 95%

“…6,76 ○ There are reports of patients with persistent or recurrent ureaplasma - positive urethritis being cured only after their sexual partner received appropriate treatment. 89 ○ There is conflicting evidence that partners of such men may be at increased risk of testing chlamydia-positive. 46,90 ○ In the absence of randomised prospective studies it would be prudent to treat partners of micro-organism-negative NGU concurrently to potentially reduce female morbidity and risk of recurrent/persistent NGU in the index men.…”

Section: Sexual Contacts/partnersmentioning

confidence: 99%

“…○ There are reports of patients with persistent or recurrent ureaplasma - positive urethritis being cured only after their sexual partner received appropriate treatment. 89…”

Section: Sexual Contacts/partnersmentioning

confidence: 99%

See 2 more Smart Citations

2015 UK National Guideline on the management of non-gonococcal urethritis

Horner¹,

Blee

O'Mahony

et al. 2015

Int J STD AIDS

View full text Add to dashboard Cite

We present the updated British Association for Sexual Health and HIV guideline for the management of non-gonococcal urethritis in men. This document includes a review of the current literature on its aetiology, diagnosis and management. In particular it highlights the emerging evidence that azithromycin 1 g may result in the development of antimicrobial resistance in Mycoplasma genitalium and that neither azithromycin 1 g nor doxycycline 100 mg twice daily for seven days achieves a cure rate of >90% for this micro-organism. Evidence-based diagnostic and management strategies for men presenting with symptoms suggestive of urethritis, those confirmed to have non-gonococcal urethritis and those with persistent symptoms following first-line treatment are detailed.

show abstract

Section: Sexual Contacts/partnersmentioning

confidence: 95%

Section: Sexual Contacts/partnersmentioning

confidence: 99%

See 1 more Smart Citation

2015 UK National Guideline on the management of non-gonococcal urethritis

Horner¹,

Blee

O'Mahony

et al. 2015

Int J STD AIDS

View full text Add to dashboard Cite

show abstract

“…35,64,98 There are reports of patients with persistent or recurrent ureaplasma - positive urethritis being cured only after their sexual partner received appropriate treatment. 99 …”

Section: General Advicementioning

confidence: 99%

2016 European guideline on the management of non-gonococcal urethritis

et al. 2016

View full text Add to dashboard Cite

We present the updated International Union against Sexually Transmitted Infections (IUSTI) guideline for the management of non-gonococcal urethritis in men. This guideline recommends confirmation of urethritis in symptomatic men before starting treatment. It does not recommend testing asymptomatic men for the presence of urethritis. All men with urethritis should be tested for Chlamydia trachomatis and Neisseria gonorrhoeae and ideally Mycoplasma genitalium using a nucleic acid amplification test (NAAT) as this is highly likely to improve clinical outcomes. If a NAAT is positive for gonorrhoea, a culture should be performed before treatment. In view of the increasing evidence that azithromycin 1 g may result in the development of antimicrobial resistance in M. genitalium, azithromycin 1 g is no longer recommended as first line therapy, which should be doxycycline 100 mg bd for seven days. If azithromycin is to be prescribed an extended course of 500 mg stat, then 250 mg daily for four days is to be preferred over 1 g stat. In men with persistent NGU, M. genitalium NAAT testing is recommended if not previously undertaken, as is Trichomonas vaginalis NAAT testing in populations where T. vaginalis is detectable in >2% of symptomatic women.

show abstract